Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis
Open Access
- 10 August 2021
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (23), 2617-2631
- https://doi.org/10.1200/jco.20.03238
Abstract
PURPOSE To analyze the prevalence of homologous recombination deficiency (HRD) in patients with pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS We conducted a systematic review and meta-analysis of the prevalence of HRD in PDAC from PubMed, Scopus, and Cochrane Library databases, and online cancer genomic data sets. The main outcome was pooled prevalence of somatic and germline mutations in the better characterized HRD genes ( BRCA1, BRCA2, PALB2, ATM, ATR, CHEK2, RAD51, and the FANC genes). The secondary outcomes were prevalence of germline mutations overall, and in sporadic and familial cases; prevalence of germline BRCA1/2 mutations in Ashkenazi Jewish (AJ); and prevalence of HRD based on other definitions (ie, alterations in other genes, genomic scars, and mutational signatures). Random-effects modeling with the Freeman-Tukey transformation was used for the analyses. PROSPERO registration number: (CRD42020190813). RESULTS Sixty studies with 21,842 participants were included in the systematic review and 57 in the meta-analysis. Prevalence of germline and somatic mutations was BRCA1: 0.9%, BRCA2: 3.5%, PALB2: 0.2%, ATM: 2.2%, CHEK2: 0.3%, FANC: 0.5%, RAD51: 0.0%, and ATR: 0.1%. Prevalence of germline mutations was BRCA1: 0.9% (2.4% in AJ), BRCA2: 3.8% (8.2% in AJ), PALB2: 0.2%, ATM: 2%, CHEK2: 0.3%, and FANC: 0.4%. No significant differences between sporadic and familial cases were identified. HRD prevalence ranged between 14.5%-16.5% through targeted next-generation sequencing and 24%-44% through whole-genome or whole-exome sequencing allowing complementary genomic analysis, including genomic scars and other signatures (surrogate markers of HRD). CONCLUSION Surrogate readouts of HRD identify a greater proportion of patients with HRD than analyses limited to gene-level approaches. There is a clear need to harmonize HRD definitions and to validate the optimal biomarker for treatment selection. Universal HRD screening including integrated somatic and germline analysis should be offered to all patients with PDAC.This publication has 91 references indexed in Scilit:
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature, 2012
- Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomesThe Journal of Pathology, 2012
- The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancerThe Journal of Pathology, 2012
- ATM Mutations in Patients with Hereditary Pancreatic CancerCancer Discovery, 2012
- GRADE guidelines: 7. Rating the quality of evidence—inconsistencyJournal of Clinical Epidemiology, 2011
- BRCA Germline Mutations in Jewish Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2009
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986